argenx SE (NASDAQ:ARGX) Shares Acquired by Moore Capital Management LP

Moore Capital Management LP raised its position in argenx SE (NASDAQ:ARGX - Free Report) by 54.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,000 shares of the company's stock after buying an additional 12,000 shares during the period. Moore Capital Management LP owned about 0.06% of argenx worth $20,910,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. GeoWealth Management LLC lifted its position in argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after buying an additional 18 shares in the last quarter. Whipplewood Advisors LLC purchased a new stake in shares of argenx in the 4th quarter valued at $37,000. Global Retirement Partners LLC boosted its stake in shares of argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after purchasing an additional 48 shares during the period. FIL Ltd purchased a new stake in shares of argenx during the fourth quarter worth $38,000. Finally, Jones Financial Companies Lllp boosted its stake in shares of argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after buying an additional 61 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $720.00 price objective on shares of argenx in a research report on Tuesday, April 8th. Robert W. Baird upgraded shares of argenx from a "neutral" rating to an "outperform" rating and set a $680.00 target price for the company in a research note on Tuesday. Guggenheim reduced their target price on argenx from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a report on Friday, May 9th. William Blair reaffirmed an "outperform" rating on shares of argenx in a report on Friday, February 28th. Finally, Baird R W upgraded shares of argenx from a "hold" rating to a "strong-buy" rating in a research report on Tuesday. One investment analyst has rated the stock with a hold rating, twenty have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, argenx presently has an average rating of "Buy" and a consensus target price of $698.11.

argenx Price Performance

ARGX stock traded up $29.48 during midday trading on Thursday, reaching $561.75. 694,499 shares of the company's stock traded hands, compared to its average volume of 322,952. The business has a 50-day moving average price of $592.11 and a two-hundred day moving average price of $612.79. argenx SE has a fifty-two week low of $356.38 and a fifty-two week high of $678.21. The company has a market capitalization of $34.30 billion, a P/E ratio of -638.35 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.32 by $0.26. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, research analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.